← Back to Search

RxWell for Mood Disorders (RxWell Trial)

N/A
Waitlist Available
Led By Murat Kaynar
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-op 1 month, post-op 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to improve peri-operative care, hasten recovery, and save resources for UPMC ISD by using a platform called RxWell.

Who is the study for?
This trial is for individuals scheduled for elective orthopedic surgery at select UPMC hospitals, who are experiencing high levels of anxiety or depression as measured by specific tests. Participants must have access to a smartphone or tablet and not require immediate intervention for severe mood disorders.
What is being tested?
The SuRxgWell study is testing the RxWell platform's effectiveness in managing mood disorders like anxiety and depression to improve recovery outcomes after surgery. The trial will compare patients using RxWell with those not using it.
What are the potential side effects?
Since this trial involves a digital platform for mood management rather than medication, traditional side effects are not expected. However, users may experience discomfort if they find the technology challenging or if it triggers emotional responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-op 1 month, post-op 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-op 1 month, post-op 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cumulative Opioid Consumption in Oral Morphine Equivalent (OME) (mg)
Secondary study objectives
Opioid prescription refills by 3 months
Pain at Rest
Pain with Movement
+1 more
Other study objectives
Surgical outcomes: rate of readmission
Surgical outcomes: same day discharge

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Intervention: RxWellExperimental Treatment1 Intervention
RxWell Intervention. Subjects will receive standard of care and digital cognitive behavioral intervention by using the application RxWell. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes and will complete GAD-7 (Generalized Anxiety Disorder Scale) and PHQ-8 (Patient Health Questionnaire for Depression) every 2 weeks within the RxWell application.
Group II: ControlActive Control1 Intervention
No intervention (No RxWell). Subjects will receive standard of care and education regarding potential resources for anxiety and depression. Subjects will complete questionnaires via REDCap assessing primary and secondary outcomes
Group III: Control (screen failures)Active Control1 Intervention
We will collect data on patient outcomes for patients that did not meet criteria for the RxWell intervention.

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,607 Previous Clinical Trials
3,329,785 Total Patients Enrolled
9 Trials studying Mood Disorders
1,500 Patients Enrolled for Mood Disorders
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,172,473 Total Patients Enrolled
4 Trials studying Mood Disorders
661 Patients Enrolled for Mood Disorders
University of PittsburghLead Sponsor
1,792 Previous Clinical Trials
16,359,836 Total Patients Enrolled
8 Trials studying Mood Disorders
800 Patients Enrolled for Mood Disorders
Murat KaynarPrincipal InvestigatorUPMC Department of Anesthesiology and Perioperative Medicine
Jacques Chelly, MD, PhD, MBAPrincipal InvestigatorUPMC Department of Anesthesiology and Perioperative Medicine

Media Library

-RxWell Clinical Trial Eligibility Overview. Trial Name: NCT05658796 — N/A
Mood Disorders Research Study Groups: Control, Intervention: RxWell, Control (screen failures)
Mood Disorders Clinical Trial 2023: -RxWell Highlights & Side Effects. Trial Name: NCT05658796 — N/A
-RxWell 2023 Treatment Timeline for Medical Study. Trial Name: NCT05658796 — N/A
~31 spots leftby Jul 2025